Zolbetuximab

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2…

What it is used for

VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

Hypersensitivity Reactions, including anaphylaxis, and infusion related reactions.
Severe Nausea and Vomiting.

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Zolbetuximab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/zolbetuximab
APA 7th: sofidex. (2026, August 3). Zolbetuximab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/zolbetuximab
AMA 11th: Zolbetuximab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/zolbetuximab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.